126,947 Shares in Pfizer Inc. $PFE Acquired by Cherokee Insurance Co

Cherokee Insurance Co acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 126,947 shares of the biopharmaceutical company’s stock, valued at approximately $3,077,000. Pfizer comprises approximately 1.3% of Cherokee Insurance Co’s investment portfolio, making the stock its 26th largest holding.

Several other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Geode Capital Management LLC increased its position in Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after buying an additional 1,820,634 shares during the last quarter. Northern Trust Corp raised its holdings in Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after buying an additional 3,943,397 shares in the last quarter. Amundi lifted its position in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock worth $767,709,000 after acquiring an additional 838,198 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.3%

Shares of PFE stock opened at $25.84 on Thursday. The firm has a market capitalization of $146.92 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm’s fifty day simple moving average is $24.77 and its 200 day simple moving average is $24.42. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is currently 100.00%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PFE shares. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.